When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. First, the balance sheet is in at least decent shape. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. But there is no question some big-name stocks performed better than others along the way. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. quotes delayed at least 15 minutes, all others at least 20 minutes. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Without NeoCart, that burn likely comes down. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. You never know when they will suddenly go on a squeeze. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. The Motley Fool recommends Moderna Inc. Ocugen Inc. is a clinical stage biopharmaceutical company. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. The FDA's decision not to issue EUA really wasn't all that surprising, though. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. The short answer is: everything. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. Theres even room for more lines. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. It brings in no revenue. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. If you missed that action, you missed all the gains. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. Type a symbol or company name. Hold) without suggesting a price target. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. However, sometimes the optimism isn't justified. But if they do, Ocugen stock at the least looks like an intriguing bet. quotes delayed at least 15 minutes, all others at least 20 minutes. For priority reviews, the timeline for an approval decision is reduced to six months. Ocugens Big Run: One company that has been a home-run investment in the last year has been biotech stock Ocugen Inc (NASDAQ:OCGN). COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. Instead, this appears destined to join the long list of failed biotech startups. I will concede this: The one great thing about the stock market is there is a style for everyone. The Motley Fool has a disclosure policy. If Ocugen goes up, you can still profit. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. (See OCGN stock analysis on TipRanks). So far, that merger hasnt worked out for Histogenics former shareholders. That's right -- they think these 10 stocks are even better buys. Other than an emphasis on cell therapies, the companies had almost nothing in common. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. As of this writing, Matt did not hold a position in any of theaforementioned securities. Histogenics itself highlights the risks involved in small-cap biotech. Maybe. Ocugen estimates the drug could have as many as 63,000 potential patients. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). Do not expect a recovery in Ocugen stock. The company initiated its Phase 3 trial of OCU300 back in July 2018. However, the marriage of Histogenics and Ocugen looks destined to end in a suicide pact instead of a mere divorce. Theres even room for more lines. Accordingly, the analyst rates OCGN a Neutral (i.e. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Click here to see what Matt has up his sleeve now. The combined company has an agreement to sell the rights to NeoCart to privately held Medavate, leaving it reliant on Ocugens pipeline. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Written by Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Learn More. All rights reserved. The second is that the balance sheet still needs some help. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. The chances of anything more are small but the rewards could be huge. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. All rights reserved. Guys, theres no revenue here! *Stock Advisor returns as of June 7, 2021. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. If they have solid financials, but their trials continually fail, they will likely not succeed. It has real management. It has real products. Written by The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. However, even from this limited vantage point, OCGN appears destined to fail. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. Please check your download folder. The median estimate. It's hard to say for sure. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. What Is the Best EV Stock to Buy Now? Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Ocugen Inc First Quarter 2022 Financial Results and Recent Business Highlights 04/21/2022 Noble Capital Markets' Eighteenth Annual Investor Conference 03/14/2022 34th Annual ROTH Conference 02/25/2022 Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 It is very important to do your own analysis before making any investment. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." But it does mean something. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. Thats the thing with these low-priced penny stocks. Source: Chart courtesy of StockCharts.com. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. market." Bharat Biotech has a history of successful vaccine commercialization in South Asia. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. Typically, I care little about financials with biotechs. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Like other life sciences companies involved in Covid-19 vaccine. Copyright *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. Copy and paste multiple symbols separated by spaces. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Thats why we give you a wide range of Options on stocks, indices, commodities and FX. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. Copy and paste multiple symbols separated by spaces. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. Even before that point, the most promising candidates generally can find funding. The Motley Fool->. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. This can prove to be a costly lesson to learn. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Thats one of the best rallies weve seen in that amount of time (95 trading sessions, 136 days). The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. Do Not Sell My Personal Information (CA Residents Only). And while Ocugen will need more capital at some point, the company at least has time to push OCU300 forward and get its story out to investors. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. Investors were hopeful that the small drugmaker would be able to win U.S. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. The company stated that it will pursue a path to file for full FDA approval of Covaxin. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. Ramakanth believes the broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. Keith Speights for However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. This decision. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. With this, the newly formed Ocugen initiated a 60:1 reverse stock split. The OCGN stock forecast 2022 outlook suggests that Ocugen's stock may struggle in the short term. 2023 InvestorPlace Media, LLC. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. Unfortunately for investors, the U.S. FDA did not grant Covaxin an Emergency Use Authorization and instead recommended in June that Ocugen opt for a Biologic License Application that will likely require additional Phase 3 testing. For now, though, what happens in India stays in India. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. However, when that occurred, Ocugen stock lost most of its value. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Sign up below to get this incredible offer! The statistics support having long-term exposure to this asset class. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. The equity has experienced a continual decline for years. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. Most biotech companies have intriguing stories on paper; Ocugen is no different. Making the world smarter, happier, and richer. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. That's not going to happen now. Start trading Options with Saxo today. This requires no immediate effort on your part. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. The Ocugen deal is a way to salvage some limited value. Investing is always a game of balancing risk and reward. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. As of this writing, Vince Martin has no positions in any securities mentioned. Part of the proceeds will be used to support its partnership with Bharat. Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. The stock had gained some traction after they announced the. The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. It announced on Dec. 9 of last year 17 months later that it was 50% through enrollment. 1125 N. Charles St, Baltimore, MD 21201. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. You canfollow Will on Twitterat @HealyWriting. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. Create your Watchlist to save your favorite quotes on Nasdaq.com. In this case, shares rallied about four-fold in just a few days. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. Our 3 Top Picks. Here are three prudent steps to take. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. Can you feel the ground moving beneath your feet? Lorem ipsum dolor sit amet, consectetur adipiscing elit. The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. A $30 million market capitalization doesnt mean Ocugen has no chance. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Copyright 2023 InvestorPlace Media, LLC. But just because a company does not have crippling debt doesnt mean its a buy. The odds of Ocugen stock winding up at zero are material. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. Ocugen isnt a promotional, fly-by-night penny stock. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. What Is the Best EV Stock to Buy Now? It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. Conditions have only become worse since that time. Maybe OCGN stock will be one of them again. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). These options will be cheaper than owning the stock itself. It means that institutional investors focused on the sector largely have passed on the pipeline. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. Honestly, OCGN stock is unlikely to survive. MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Ocugen In 2021, Beyond: Optimism about Covaxin coupled with massive short squeezes in a handful of popular social media stocks sent Ocugen shares skyrocketing up to as high as $18.77 in February 2021. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. If they invent a miracle treatment for a condition, the money will find its way to the stock. Type a symbol or company name. When the market crashed during the U.S. pandemic outbreak in March, shares of vaccine makers understandably soared as work began on developing vaccines to fight COVID-19. Copyright The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. Custom BMW. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our.